Clinical Trial Search

Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants

Primary: Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) — 0.92; 0.95 AECOPD events/person-year — p=0.941

Primary: Percentage of Participants Whose Post-albuterol Forced Expiratory Volume in One Second (FEV1) Was <80% Predicted Normal — 70; 30 percentage of participants

Primary: Number of Participants With Accurate Classification of Irreversible Airflow Obstruction — 10; 5 Participants

Primary: Change From Baseline in Trough FEV1 at Treatment Visit Day 7 Compared to Placebo. — -0.0282; -0.0156; 0.0540; 0.0806 liters — p=0.9730

Primary: Number of Participants Who Received COPD Prescription for Maintenance Treatment at Baseline — 735; 68; 554; 105 Participants

Primary: Mean Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) — 0.78; 0.71 AECOPD events/year — p=0.645

Primary: Exertional Dyspnea Intensity at Isotime Exercise. — 3.9; 3.4 units on a scale — p=0.090

Primary: Self-reported Intake of Fruit and Vegetables (Number of Portions Per Day); — 1.9; 6.1 Portions per day

Primary: Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL — 0.99; 1.21; 1.09; 1.17 Exacerbations per year — p=0.0638

Primary: Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL — 1.19; 1.03; 1.24 Exacerbations per year — p=0.6490

Primary: Change From Baseline in Inspiratory Capacity (IC) at Isotime — 0.0035; 0.07 liter — p=0.0087

Primary: Trough Forced Expiratory Volume in One Second (FEV1) — 1.204; 1.063 Liters

Primary: Device Tidal Volume — 180 mL

Primary: FEV1, E0-4; the Average Value at Visit 5 From Before to 4 Hours After Morning Dose (Peak Effect) — 0.21; 0.17; 0.14; 0.16 Litre

Primary: Mean Change From Baseline in Peak FEV1 (Over 3 Hours) at Week 4 — 0.203; 0.209; 0.257; 0.196 Liters — p=<0.001

Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) at 12 Weeks — 1.408; 1.301 Liters

Primary: FEV1 AUC0-24 on Day 29 — 0.166; -0.083 Liters

Primary: Baseline Resting Cardiac Index (CI) — 2.4; 2.36 L/min/m^2 — p=0.85

Primary: Death or Hospitalization, Whichever Occurs First — 34.2; 36.4 Composite events/100 person-years — p=0.52

Primary: Percent Change From Baseline in BMD of the Lumbar Spine — -0.093; 0.379; -0.120 Percentage

Primary: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 3 Hours (AUC0-3h) After 4 Weeks of Treatment. — 0.250; -0.086…

Primary: Time Spent in Physical Activity as Measured by Upright Time (Minutes Per Day) Monitored by ActivPal Monitor — 278; 269; 293; 285 minutes per day

Primary: FEV1 AUC0-12 — 1.477; 1.497; 1.443; 1.514 Liter

Primary: Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) — 0.0009; 0.1055; 0.1333; 0.1336 liters — p=0.0043

Primary: Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-24hr — 0.0953; -0.0429 L/sec*hr

Primary: Total Total Transient Dyspnea Index (TDI) Score After 6 Weeks of Treatment QVA149 Compared to Placebo — 7.34; 7.33; 0.98; -0.38 Units on a scale

Primary: Patients Who Experienced at Least One Adverse Events(s) — 9; 10; 6 Participants

Primary: Change From Baseline in Normalised Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-12 hr at Day 15 on Treatment. — 0.236; 0.260; 0.015 Liters

Primary: Change From Baseline in Volume of Mucin Per Surface Area of Basal Lamina — 2.565; 1.180 micrometer^3/micrometer^2 — p=0.5305